Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Mining Press Releases.
Press releases published on August 11, 2025
Quest Resource Holding Corporation Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Generated $3.9 million in operating cash flow in the second quarter and reduced debt by $6.6 million year to date Posted sequential improvements in gross profits and adjusted EBITDA Roll out of Operational Excellence Initiatives is on track and continuing …
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 11, 2025
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 …
TELA Bio Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended …
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 11, 2025
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 million Transaction …
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 11, 2025
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase …
Fluence Energy, Inc. Reports Third Quarter 2025 Results; Reaffirms Fiscal Year 2025 Guidance
GlobeNewswire
·
August 11, 2025
ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its …
Mercury Systems Reports Fourth Quarter and Fiscal 2025 Results
GlobeNewswire
·
August 11, 2025
Record Q4 FY25 Bookings of $341.5 million; book-to-bill of 1.25 Record backlog of $1.40 billion; up 6% year-over-year Q4 FY25 Revenue of $273.1 million; GAAP net income of $16.4 million; and adjusted EBITDA of $51.3 million Q4 FY25 Operating Cash Flow of $ …
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 11, 2025
FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026 Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDA Company accelerates Anaphylm global expansion strategy to Canada and the EU Company to host …
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
GlobeNewswire
·
August 11, 2025
Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclib OPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on …
Rapid7 to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 11, 2025
BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a leader in threat detection and exposure management, today announced that the company will be attending the following conferences: The Canaccord Genuity 45th Annual Growth Conference in …
USA Rare Earth Reports its Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
STILLWATER, Okla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (“USAR” or the “Company”) today announced its financial and operational results for the second quarter and six months ended June 30, 2025. Second Quarter Highlights …
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 …
Xenon Reports Second Quarter 2025 Financial Results & Business Update
GlobeNewswire
·
August 11, 2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated – Phase 1 healthy volunteer …
Plug Power Second Quarter 2025 Highlights
GlobeNewswire
·
August 11, 2025
• Execution on Project Quantum Leap helps accelerate business sales growth and financial performance • Q2 revenue up 21% year-over-year, driven by broad hydrogen demand LATHAM, N.Y., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a …
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
GlobeNewswire
·
August 11, 2025
Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO as Dr. Han Ying transitions to …
Standard BioTools Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host …
Harrow Announces Second-Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million Cash and cash equivalents of $53.0 …
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 11, 2025
Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment …
Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conference »
GlobeNewswire
·
August 11, 2025
Daix (France), New York City (New York, Etats-Unis), le 11 aout 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la …
DarkIris Inc. Announces Closing of Initial Public Offering
GlobeNewswire
·
August 11, 2025
Hong Kong, Aug. 11, 2025 (GLOBE NEWSWIRE) -- DarkIris Inc. (Nasdaq: DKI) (the “Company” or “DarkIris”), a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games through various third-party digital …